There is great concern regarding the increasing problem of drug resistance among salient organisms, termed ''ESKAPE'' pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enerobacter spp.), that are responsible for the majority of hospitalacquired infections [1] [2] [3] . Frequently cited as one of the factors fueling alarm is the shrinking antimicrobial armamentarium available to clinicians for illnesses caused by these pathogens. There are, however, drugs available on the global market outside the United States with demonstrated activity against some of these organisms, as well as efficacy in treatment of consequent infections. For example, there are widely utilized drugs effective against staphylococcal infections, including methicillinresistant S. aureus (MRSA), that have not yet entered the US pharmaceutical marketplace. Efforts focused on seeking marketing approval for such drugs would (1) result in a better understanding of safe use prior to market entry and (2) possibly lessen the regulatory demand for larger safety databases for registrational review when compared with bringing a new molecular entity (NME) to market. It would also have the additional benefit, over standard applications, of an ethnically diverse safety database to bolster a New Drug Application (NDA) to the US Food and Drug Administration (FDA).
One such drug is fusidic acid (FA), which has been in clinical use for the treatment of staphylococcal infections outside the United States since 1962. FA is marketed in at least 23 countries with an estimated 21.3 million prescriptions annually (2006) , of which 1.3 million were for oral use (IMS data-on file). This widespread use has resulted in a comprehensive collection of spontaneous adverse event reports related to FA as well as citations regarding clinical use since FA entered the pharmaceutical market 48 years ago. These safety data are accessible and provide insight into events that might be expected should FA become available for use in the United States. Precedents for the pooling of such data exist and have supported other drugs as they enter the US market, such as the tinidazole NDA by Presutti Labs (Nos. 21-618, 21-681, and 21-682 for trichomoniasis, giardiasis, and amebiasis, respectively) on 14 May 2005 and the quinine sulfate NDA for the treatment of uncomplicated Plasmodium falciparum infection) by Mutual Pharmaceutical Co on 8 August 2005 . Clinical safety data were systematically extracted from the published literature according to a predefined review process. Each publication needed to meet clear inclusion criteria to be included in the authors' safety database (Table 1) .
FUSIDIC ACID SAFETY CONSIDERATIONS IN FOREIGN LABELS
As in previously reviewed NDAs that incorporate foreign data [4] , there is value in assessing foreign labeling to characterize safety experience and in identifying likely safety concerns for the US population should marketing approval be sought and granted. New Zealand, Canada, the United Kingdom, and Ireland have approved FA for use and have readily available product labels [5, 6] . The most common dosing schedule in these labels is 500 mg orally, taken 3 times daily. The 2 most frequent approved indications in these labels are skin infections and osteomyelitis. The most common organ systems for which safety data are cited in the labeling are gastrointestinal, neurologic, allergic, and hematologic. Frequent adverse events (AEs) described for these systems are:
1. Gastrointestinal: flatulence, vomiting, nausea, hepatic transaminase elevation, diarrhea, anorexia, abdominal pain, jaundice, dyspepsia 2. Allergic: rash, pruritis, anaphylaxis, angioneurotic edema, urticaria, edema 3. Hematologic: leukopenia, anemia, neutropenia, thrombocytopenia, pancytopenia, granulocytopenia, agranulocytosis 4. Neurologic/psychiatric: headache, blurred vision, dizziness, lethargy, psychic disturbance
The frequency of most events was low or occurred at a low enough severity that inclusion in labeling was sufficient for foreign regulatory authorities to ensure safe and effective use of FA. Various precautions regarding concomitant drug administration and use in patients with impaired liver function are included in the labeling to limit potential hepatic AEs.
FUSIDIC ACID SAFETY DATA POOLED FROM THE PUBLISHED LITERATURE
The published literature was reviewed for evidence of use of oral FA alone or use of oral FA after intravenous use of FA in human subjects so that clinical safety data could be pooled. The primary objective was to determine if the available data adequately reflected foreign product labeling and to describe AEs associated with FA use according to character, frequency, and severity.
In order to identify relevant citations that included clinical safety data, a literature search was conducted using a medical subject heading (MeSH) query for ''fusidic acid'' in the Medline database A medical reviewer (board certified in Infectious Diseases) conducted an independent audit of 10 randomly selected articles midway through the review process to assess data extraction quality and clinical relevance. Any relevant findings in this audit resulted in rereview of the articles and modification of the data extraction strategy for the remaining articles.
A total of 102 articles published from 1962 to 2007 were reviewed, resulting in inclusion of 19,045 subjects who had been exposed to oral FA for a variety of indications ( Table 2 ). The majority of these studies (n 5 80) were open label (78%). There were 13 blinded (single or double) studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and 21 randomized trials, 12 of which were controlled, 5 with placebos [10, 16, 17, 20, 21] . One study, by Goncalves and Thorn [22] , accounted for the majority (n 5 14,672) of exposures. This uncontrolled, nonrandomized, postmarketing, observational study assessed the safety and efficacy of oral FA (with and without concomitant topical FA use) in a general practice setting. The majority of patients experienced no AEs or reported only minor (nonserious) events, without description of the frequency, severity, or character of these events. The severe events (n 5 153) listed were uncharacterized and there were 780 unaccounted patients in the study, making it difficult to draw any conclusions regarding safety. Therefore, this study was not included in the aggregated data set, though independent observations from this citation alone could complement other findings.
The duration of dosing was assessed by determining the patient exposure to FA and daily consumption. This information could be determined in 70 of the citations referenced. This subset of studies contained subjects exposed to FA from 1 day to 240 days with the daily dose ranging from .25 g to 3.75 g. This considerable variability, combined with the absence of explicit assignment of the adverse events to the specific patient's drug exposure, was of concern. It was concluded that averaging both daily drug consumption and duration of exposure introduced too many assumptions, such that the validity of AE profiling against exposure time would be in doubt.
Of the 4373 subjects included in the articles reviewed (excluding Goncalves and Thorn [22] ), 3287 (75%) had dosing and scheduling information available; the majority of these subjects (n 5 2058, 62.6%) received a dose of 500 mg per day or higher. The other most frequent dosing schedule (n 5 969, 29.5%) was 250 mg twice daily, concordant with the reviewed product labels. The mean daily dose used for treatment of skin infections ranged from 500 mg to 1500 mg and a large proportion of patients received 500 mg, 2 or 3 times daily. The mean daily dose used for treatment of osteomyelitis ranged from 1500 mg to 3000 mg. Fewer data were available for osteomyelitis and there were no controlled trial data (no osteomyelitis citations had a comparator arm). Treatment durations were likewise disparate; skin-infection-treated subjects were rarely treated for .10 days (2.4%) and osteomyelitis-treated subjects were rarely treated for ,10 days (7.9%).
There was marked variability in the methodologies used to collect safety data in the medical literature surveyed ( Table 3 ). The majority of the citations (n 5 74) did not address how such data were collected. As described elsewhere, the manner in which safety data are collected can impact the overall safety profile of a drug; spontaneous reporting of AEs is less frequent than patient reporting [4] . Both methods have disparate sources of bias (eg, recall bias or reporting bias) with consequent variation in the perceived safety profile of a drug. The majority of studies of patients treated for skin infections (n 5 20) with oral FA were uncontrolled observations (n 5 14, 70%), and information regarding how the safety data were collected was not included. When information was provided (exclusive of the Goncalves and Thorn citation [22] ), the methods were either not detailed (n 5 12, 60%) or it was specified that data were collected using specific questionnaires (n 5 7, 35%).
Safety concerns reflecting the character, seriousness, and frequency of adverse events are summarized. Of greatest concern are the 61 deaths (independent of treatment indication) identified in 12 articles. A large proportion of these deaths (n 5 33, 54.1%) were identified in 1 article and were insufficiently characterized to assess drug exposure or attribution of drug and outcome [23] . Variable amounts of detail were available for the remaining cases (n 5 28, 45.9%), and after full review, none provided sufficient data to demonstrate causal attribution to FA [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . In addition to death, hepatic AEs require specific consideration. As drugs marketed in the European Union have often elicited hepatotoxicity safety signals that have precluded their approval in the United States (eg, ibufenac, perhexiline, alpidem), specific attention was placed on hepatic abnormalities during the literature survey. Two patients had documented concomitant elevation of hepatic enzymes and bilirubin, a combination that warrants further review. One patient was receiving concomitant protease inhibitor-based highly active antiretroviral therapy and was found to have supratherapeutic levels of FA, saquinavir, and ritonavir, most likely due to cytochrome P450 CYP3A4 inhibition by the protease inhibitors. The elevations in bilirubin and hepatic enzyme levels could not conclusively be attributed to FA exposure due to concomitant exposure with a known potentially hepatotoxic agent [34] . The second case was confounded due to AIDS co-morbidity and concomitant use of potentially hepatotoxic agents (sulfadoxine and pyrimethamine, Fansidar) as well as a CYP3A4 inhibitor (ketoconazole). In this case, elevations in bilirubin and hepatic enzyme levels may have been attributable to disease state and/or use of a known hepatotoxic drug [31] .
In the interest of summarizing the surveyed literature with regard to character and frequency of adverse events, focus was placed on the most salient experience in the published literature, which is in skin infections (20 citations) and osteomyelitis (19 citations) . When the assessment of FA-treated subjects was limited to those who had received treatment for skin infections in comparative studies, 2066 total subjects were identified, of whom 876 were treated with FA and 1190 were treated with a comparator. The overall character of AEs was similar among these pooled groups with a prevalence of gastrointestinal, neurologic, and allergic events. This AE profile was comparable to the 608 total AEs captured for all skin infection subjects treated with oral FA, independent of study design. The majority of those events were classified as gastrointestinal (58%), constitutional (6.1%), neurologic (3.3%), allergic (4.6%), and other (27%), with most of the events occurring with the common treatment regimen of 6-10 days' duration ( Table 4 ). The most common treatment duration that resulted in an AE was 6-10 days (80% of events) and there are no data on the duration associated with 71 (12%) of these events.
There were 429 FA-treated subjects in 19 unique articles on osteomyelitis, but none contained comparator arm information. These studies were further confounded by the use of preceding intravenous FA (31% of subjects). The AEs for subjects receiving oral FA for osteomyelitis were similar in character to skin infection subjects, with the majority of events classified as gastrointestinal (30%), hepatobiliary (33%), or hematologic (7.4%). There were 9 hepatobiliary events in this group, yet none was persuasively linked to oral FA exposure. The subject reported by Biswas et al [31] was receiving numerous concomitant medications, including hepatotoxic agents. The subjects reported by Ernst [35] were treated with high-dose FA (mean daily dose of 3 g) and the reference provided insufficient detail to assess the 4 subjects noted to have elevated hepatic enzyme levels.
NON-US SPONTANEOUS SAFETY REPORTS
Because FA has been in clinical use since 1962 in non-US markets, regulatory authorities around the globe have established their own spontaneous reporting databases for the purpose of capturing postmarketing safety reports in a systematic, standardized fashion. The majority of these data sources have restricted access controlled by each local regulatory agency and could not be accessed. In the UK, however, the Medicines and Healthcare Products Regulatory Agency provides redacted safety reports in predefined formats. The report obtained for FA was wholly inadequate for the purpose of our safety review. In contrast, the international safety database VigiBase proved to be of significantly greater value. VigiBase is a centralized database of spontaneous safety reports that is managed by the Uppsala Monitoring Centre (UMC) and under the remit of the World Health Organization (WHO). It is fully compliant with the Medical Dictionary for Regulatory Activities (MedDRA) and employs both the WHO Adverse Drug Reaction Terminology (WHOART) and WHO Drug dictionaries. As of April 2007, VigiBase comprised more than 3.8 million case reports submitted from 84 countries, with approximately 50,000 cases reported quarterly. Full data extracts of all adverse event reports for FA received and processed at the UMC were requested with categorization by route of administration to cover intravenous, topical, and oral administration. A total of 824 unique patients were identified in the VigiBase data extract. These 824 patients had a primary reference of an AE linked to the oral formulation of FA, and the data extract was limited to unique records (duplicates were excluded) as well as the most recent updated report (updated reports for the same event were removed).
The majority of cases detailed in the VigiBase data extract were in the adult and geriatric populations (88.0%), with no significant difference in gender (48.1% female and 50.5% male); neonate and pediatric cases constituted a smaller proportion of the cases (.4% and 5.8%, respectively), and 5.9% of cases were not specifically categorized. There were a total of 1476 events among these 824 subjects, with the largest number of reports originating from Sweden, France, Great Britain, and Australia. Events occurred most frequently in the following categories: hepatobiliary, allergic, hematologic, gastrointestinal, and neurologic, which is in agreement with current product labeling and safety data identified from the published literature. There were 50 patients identified as having been treated for a skin infection (as defined by one of the terms in Table 5 ) in the VigiBase data extract, who were dosed, on average, 500 mg 3 times daily. Treatment duration was captured in the AE report for 40 of these subjects; the majority (n 5 35, 85%) received <14 days of therapy. For the 18 subjects who were treated for osteomyelitis, 12 had treatment duration as a captured variable, of which the majority (n 5 8, 67%) received <14 days of FA therapy.
A total of 83 of the AEs (5.6% of the 1476 events) were directly associated with skin infections of which the majority were categorized as allergic or hepatobiliary. A total of 34 events (2.3% of all events) were associated with treatment for osteomyelitis. There were no events that exceeded 10 in number per system category for osteomyelitis, but hepatobiliary and gastrointestinal events remained prominent (Table 6 ). There were no associated deaths in this group, which is notable since the average treatment duration for osteomyelitis is substantially longer than for skin infections as was evident in both the VigiBase extract and the published literature. There was no indication of greater toxicity at higher dose or duration regimens.
Thirty-nine deaths were reported from 23 countries between 1968 and 2007 with the highest proportion from the United Kingdom (43.6%) and France (25.6%). The majority of these deaths were in the geriatric and adult age groups (61.5% and 30.8%, respectively), as well as 1 pediatric death and 2 deaths for which the demographic details were not available. Most of these deaths were deemed to be either unrelated to FA or the detail of relatedness was not provided (30% and 37.5%, respectively), with 33% (n 5 13) listed as related to FA. Among the 13 deaths listed as potentially related to FA exposure, 11 were classified under the hepatobiliary system and where the data field was available (n 5 8), the reports originated from a hospital setting or from a specialist physician (Table 7) . It is not clear from the data extract whether the primary cause for hospitalization was related to the AE or if the AE occurred during the care of the patient for another reason. Almost no reports listed a treatment indication (n 5 38, 97%); there was only 1 that identified a skin infection. This patient was an 85-year-old hospitalized Swedish woman with a postoperative wound infection who subsequently developed hepatorenal syndrome. There were no reported deaths for which the indication of osteomyelitis was listed.
DISCUSSION
This review has assessed the reporting of FA adverse events as detailed in available product labels, the published literature, and the spontaneous reporting system in non-US markets as a means of qualitatively characterizing the safety profile of oral FA with a targeted focus on skin infection treatment. Applying this approach to evaluating FA safety entailed accessing information located on regulatory agencies' safety databases, the UMC database, and the available published literature. Since only 1 oral agent in the United States, linezolid, has an FDA-approved indication for treatment of MRSA infections, all other oral agents are currently being used off-label. Characterizing the available safety data sources can provide clinicians a useful perspective of potential safety concerns experienced by non-US colleagues for this oral anti-staphylococcal agent should it eventually gain marketing approval in the US.
Based on the available data from the published literature, as well as spontaneous reports, exposure to oral FA over the previous 4 decades has been significant and clearly greatest for skin infection indications. Fusidic acid, when used orally 500 mg 2 or 3 times daily for 7 to 14 days to treat patients with skin infections, demonstrates safety characteristics consistent with the non-US product labeling, based on spontaneous reports as well as the surveyed literature. Serious events such as death and hospitalization were identified for FA-exposed patients in both the published literature as well as non-US spontaneous reports, but there were no clinically convincing cases demonstrating attribution of the adverse event to FA exposure alone. Similarly, hepatotoxic events identified in the literature were either confounded as to attribution, were lacking significant clinical information to allow critical clinical assessment, or were deemed to be potentially related, but not of significant concern, by the respective authors. Specific signals identified related to hyperbilirubinemia are unlikely due to direct toxicity, but rather are a consequence of bile transporter inhibition, similar to DubinJohnson syndrome [37] . Although reports on FA safety have continued since this safety data evaluation was conducted at the close of 2007, such reports remain consistent with current non-US product labeling and reflect the safety characteristics [38] [39] [40] . By having a better understanding of known risk characteristics, appropriate patient selection can be enhanced. Conclusions regarding overall safety must also be tempered by the data quality associated with this survey. The available literature comprised mostly open-label studies and disparate safety data collection methodologies. Few controlled studies were available and fewer yet that employed randomization or the use of a placebo. For this reason, actual rates were not explicitly provided for AEs. Regretfully, the surveyed data were inconsistent across studies, often lacked critical information regarding potential confounders, and rarely provided the methodology of safety data collection. Given the aforementioned lack of consistency across studies with absent methodologies in many of the citations, we consider the survey as providing signals that require attention in the design and conduct of adequate and well-controlled clinical studies of FA for potential registration in the United States. Access to foreign market experience is vital to maximize the data captured in future randomized controlled trials and the need remains to characterize identified safety concerns, both as monotherapy and in combination treatment regimens, where other medications may be co-administered (eg, rifamipicin). 
